Repligen’s (RGEN) Outperform Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Repligen (NASDAQ:RGEN) in a research note released on Wednesday morning, Benzinga reports. They currently have a $190.00 price target on the biotechnology company’s stock.

A number of other brokerages have also commented on RGEN. JPMorgan Chase & Co. cut their price target on Repligen from $230.00 to $200.00 and set an overweight rating on the stock in a report on Thursday, May 2nd. Deutsche Bank Aktiengesellschaft upgraded Repligen from a hold rating to a buy rating and dropped their target price for the stock from $180.00 to $155.00 in a report on Wednesday, June 26th. Guggenheim started coverage on Repligen in a report on Tuesday, June 18th. They set a neutral rating on the stock. Finally, Stephens reiterated an overweight rating and set a $170.00 target price on shares of Repligen in a report on Tuesday. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus price target of $190.88.

Repligen Stock Performance

Shares of Repligen stock opened at $167.35 on Wednesday. The firm has a market cap of $9.35 billion, a price-to-earnings ratio of 669.40, a price-to-earnings-growth ratio of 5.37 and a beta of 0.95. The stock’s 50-day moving average is $134.71 and its 200-day moving average is $166.13. Repligen has a one year low of $110.45 and a one year high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.24.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. The company had revenue of $154.07 million for the quarter, compared to analyst estimates of $154.11 million. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The company’s quarterly revenue was down 3.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.53 earnings per share. Equities analysts predict that Repligen will post 1.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Repligen news, CEO Anthony Hunt sold 20,072 shares of the business’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total transaction of $3,377,314.72. Following the transaction, the chief executive officer now owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, CEO Anthony Hunt sold 20,072 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total value of $3,377,314.72. Following the transaction, the chief executive officer now owns 163,177 shares of the company’s stock, valued at $27,456,162.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Martin D. Madaus bought 1,615 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was purchased at an average cost of $124.94 per share, for a total transaction of $201,778.10. Following the transaction, the director now directly owns 4,613 shares of the company’s stock, valued at approximately $576,348.22. The disclosure for this purchase can be found here. Company insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

Institutional investors and hedge funds have recently made changes to their positions in the company. Retirement Systems of Alabama boosted its stake in shares of Repligen by 0.4% in the fourth quarter. Retirement Systems of Alabama now owns 65,032 shares of the biotechnology company’s stock valued at $11,693,000 after buying an additional 288 shares during the period. Evoke Wealth LLC bought a new stake in shares of Repligen in the fourth quarter valued at approximately $1,955,000. International Assets Investment Management LLC boosted its stake in shares of Repligen by 18,449.1% in the fourth quarter. International Assets Investment Management LLC now owns 58,615 shares of the biotechnology company’s stock valued at $10,539,000 after buying an additional 58,299 shares during the period. Norden Group LLC boosted its stake in shares of Repligen by 1,711.6% in the first quarter. Norden Group LLC now owns 38,805 shares of the biotechnology company’s stock valued at $7,137,000 after buying an additional 36,663 shares during the period. Finally, Artemis Investment Management LLP boosted its stake in shares of Repligen by 33.8% in the first quarter. Artemis Investment Management LLP now owns 167,813 shares of the biotechnology company’s stock valued at $30,852,000 after buying an additional 42,380 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.